Tevogen Inc. cotiza a 6.68 USD y tiene una capitalización bursátil de $43M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 pa…
| Periodo | 2026-08 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | — | $-7.96 | $-1.50 | $-1.50 |
| Estimado | $-2.50 | $-1.50 | $-3.00 | $-2.50 |
| Sorpresa | — | -430.7% | +50.0% | +40.0% |
| Métrica | TVGN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -599.5% | -32.0% | -567.5% |
| Current Ratio | 0.22 | 2.84 | -2.62 |
| Debt / Equity | — | 0.28 | — |